全文获取类型
收费全文 | 138915篇 |
免费 | 12539篇 |
国内免费 | 6959篇 |
专业分类
耳鼻咽喉 | 1315篇 |
儿科学 | 2175篇 |
妇产科学 | 3141篇 |
基础医学 | 14656篇 |
口腔科学 | 2929篇 |
临床医学 | 17101篇 |
内科学 | 21763篇 |
皮肤病学 | 1926篇 |
神经病学 | 7105篇 |
特种医学 | 4639篇 |
外国民族医学 | 50篇 |
外科学 | 14600篇 |
综合类 | 20610篇 |
现状与发展 | 21篇 |
一般理论 | 19篇 |
预防医学 | 10030篇 |
眼科学 | 3743篇 |
药学 | 14360篇 |
121篇 | |
中国医学 | 6921篇 |
肿瘤学 | 11188篇 |
出版年
2024年 | 378篇 |
2023年 | 1849篇 |
2022年 | 4338篇 |
2021年 | 5872篇 |
2020年 | 4427篇 |
2019年 | 4001篇 |
2018年 | 4287篇 |
2017年 | 4002篇 |
2016年 | 3650篇 |
2015年 | 5678篇 |
2014年 | 7262篇 |
2013年 | 7517篇 |
2012年 | 10986篇 |
2011年 | 11631篇 |
2010年 | 8100篇 |
2009年 | 6610篇 |
2008年 | 8357篇 |
2007年 | 8364篇 |
2006年 | 7884篇 |
2005年 | 7161篇 |
2004年 | 5236篇 |
2003年 | 4778篇 |
2002年 | 3969篇 |
2001年 | 3327篇 |
2000年 | 3072篇 |
1999年 | 2822篇 |
1998年 | 1400篇 |
1997年 | 1301篇 |
1996年 | 1059篇 |
1995年 | 997篇 |
1994年 | 935篇 |
1993年 | 544篇 |
1992年 | 964篇 |
1991年 | 850篇 |
1990年 | 727篇 |
1989年 | 612篇 |
1988年 | 556篇 |
1987年 | 471篇 |
1986年 | 386篇 |
1985年 | 310篇 |
1984年 | 202篇 |
1983年 | 176篇 |
1982年 | 111篇 |
1981年 | 101篇 |
1979年 | 150篇 |
1978年 | 120篇 |
1977年 | 92篇 |
1974年 | 109篇 |
1973年 | 79篇 |
1972年 | 96篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
21.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
22.
23.
24.
25.
26.
27.
28.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
29.
Hepatitis E virus (HEV) is the most common cause of acute liver failure (LF) and one of the most common factors causing acute injury in acute-on-chronic LF (ACLF). When HEV-related LF occurs, a series of changes take place in both the intrahepatic environment and extrahepatic microenvironment. The changed types and distribution of immune cells (infiltrating macrophages and increased lymphocytes) in liver tissue, as well the increased proinflammatory cytokines and chemokines in the blood, indicate that the occurrence and progression of HEV-related LF are closely related to immune imbalance. The clinical features and immune reaction in the body during HEV-related acute LF (ALF) and ACLF are complicated. This review highlights recent progress in elucidating the clinical manifestations of HEV-associated ALF and ACLF and discusses the corresponding systemic immune changes and possible regulatory mechanisms. 相似文献
30.